Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 11, 1998, Pages 2956-2960

  Piddock, Laura J V ^a   Johnson, M ^a   Ricci, V ^a   Hill, S L ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLINAFLOXACIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; SPARFLOXACIN; TROVAFLOXACIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; BACTERIUM MUTANT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG TISSUE LEVEL; HAEMOPHILUS; LOWER RESPIRATORY TRACT INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 0031755687     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.11.2956     Document Type: Article

References (43)

1. Acar, J. F., and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones Clin. Infect. Dis. 24:S67-S73.
2. Andrews, J. M., D. Honeybourne, G. Jevons, N. P. Brenwald, B. Cunningham, and R. Wise. 1997. Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibreoptic bronchoscopy. J. Antimicrob. Chemother. 40:573-577.
3. Baranova, N. N., and A. A. Neyfakh. 1997. Apparent involvement of a multi-drug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Chemother. 41:1396-1398.
4. Bernard, L., J.-C. Ngyen Van, and J. L. Mainardi. 1995. In vivo selection of Streptococcus pneumoniae resistant to quinolones including sparfloxacin. Clin. Microbiol. Infect. 1:60-61.
5. Bauernfeind, A. 1997. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:639-651.
6. Brenwald, N. P., M. J. Gill, and R. Wise. 1997. The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumonias to norfloxacin. J. Antimicrob. Chemother. 40:458-460.
7. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035.
8. Brueggemann, A. B., K. C. Kugler, and G. V. Doern. 1997. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob. Agents Chemother. 41:1594-1597.
9. Cohen, M. A., M. D. Huband, J. W. Gage, S. L. Yoder, G. E. Roland, and S. J. Gracheck. 1997. In-vitro activity of clinafloxacin, trovafloxacin and ciprofloxacin. J. Antimicrob. Chemother. 40:205-211.
10. Cook, P. J., J. M. Andrews, R. Wise, D. Honeybourne, and H. Mougdil. 1995. Concentrations of OPC-17116, a new fiuoroquinolone antibacterial, in serum and lung compartments. J. Antimicrob. Chemother. 35:317-326.
11. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy 42:410-425.
12. Fas, R. J. 1997. In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. Antimicrob. Agents Chemother. 41:1818-1824.
13. Fuchs, P. C., A. J. Barry, and S. D. Brown. 1997. Susceptibility of multi-resistant Streptococcus pneumoniae to ciprofloxacin, ofloxacin and levofloxacin. J. Antimicrob. Chemother. 39:671-672.
14. Georgiou, M., R. Munoz, F. Roman, R. Canton, R. Gomezlus, J. Campos, and A. G. Delacampa. 1996. Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of gyrA and parC. Antimicrob. Agents Chemother. 40:1741-1744.
15. Goldsmith, C. E., J. E. Moore, P. G. Murphy, and J. E. Ambler. 1998. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland. J. Antimicrob. Chemother. 41:420-421.
16. HoogkampKorstanje, J. A. A. 1997. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram positive and Gram negative pathogens from the respiratory tract. J. Antimicrob. Chemother. 40:427-431.
17. Imada, T., S. Miyazaki, M. Nishida, K. Yamaguchi, and S. Goto. 1992. In vitro and in vivo antimicrobial activities of a new quinolone, OPC-17116. Antimicrob. Agents Chemother. 36:573-579.
18. Janoir, C., V. Zeller, M. D. Kitzis, N. J. Moreau, and L. Gutmann. 1996. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob. Agents Chemother. 40:2760-2764.
19. Korner, R. J., D. S. Reeves, and A. P. MacGowen. 1994. Dangers of oral fluoroquinolone treatment in community acquired upper respiratory tract infections. Br. Med. J. 308:191-192.
20. Kureishi, A., J. M. Diver, B. Beckthold, T. Schollaardt, and L. E. Bryan. 1994. Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob. Agents Chemother. 38:1944-1952.
21. Lee, B. L., A. M. Padula, R. C. Kimbrough, S. R. Jones, R. E. Chaisson, J. Mills, and M. A. Sandy. 1991. Infection complications with respiratory pathogens despite ciprofloxacin therapy. N. Engl. J. Med. 325:520.
22. Gould, I. M., K. J. Forbes, and G. S. Gordon. 1994. Quinolone resistant Haemophilus influenzae. J. Antimicrob. Chemother. 33:187-188.
23. Muñoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257.
24. Murray, C. J. L., and A. D. Lopez. 1996. Evidence-based health policy-lessons from the global burden of disease study. Science 5288:740.
25. Nakano, M., T. Deguchi, T. Kawamura, M. Yasuda, M. Kimura, Y. Okano, and Y. Kawada. 1997. Mutations in the gyrA and parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 41:2289-2291.
26. Nakashima, M., T. Uematsu, K. Kosuge, H. Kusajima, T. Ooie, Y. Masuda, R. Ishida, and H. Uchida. 1995. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans. Antimicrob. Agents Chemother. 39:2635-2640.
27. Neal, T. J., M. A. O'Donaghue, E. J. Ridgway, and K. D. Allen. 1992. In vitro activity of ten antimicrobial agents against penicillin-resistant Streptococcus pneumoniae. J. Antimicrob. Chemother. 30:39-46.
28. Pan, X.-S., and L. M. Fisher. 1996. Cloning and characterization of the parC and parE genes of Streptococcus pneumoniae encoding DNA topoisomerase IV: role in fluoroquinolone resistance. J. Bacteriol. 178:4060-4069.
29. Pankuch, G. A., M. R. Jacobs, and P. C. Appelbaum. 1995. Activity of CP99,219 compared with DU-6859a, ciprofloxacin, ofloxacin, levofloxacin, lomefloxacin, tosufloxacin, sparfloxacin and grepafloxacin against penicillin-susceptible and -resistant pneumococci. J. Antimicrob. Chemother. 35:230-232.
30. Piddock, L. J. V., and Y. F. Jin. 1992. Selection of quinolone-resistant mutants of Haemophilus influenzae and Streptococcus pneumoniae. J. Antimicrob. Chemother. 30:109-110.
31. Piddock, L. J. V., Y.-F. Jin, and M. J. Everett. 1997. Non-gyrA mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae. J. Antimicrob. Chemother. 39:609-615.
32. Piddock, L. J. V., Y. F. Jin, and V. Ricci. Characterisation of mutant Streptococcus pneumoniae with decreased susceptibility to moxifloxacin and ciprofloxacin. Unpublished data.
33. Prentice, M. 1997. Unpublished data.
34. Pumbwe, L., M. J. Everett, R. E. W. Hancock, and L. J. V. Piddock. 1996. Role of gyrA mutation and loss of OprF in the multiple antibiotic-resistance phenotype of Pseudomonas aeruginosa G49. FEMS Microbiol. Lett. 143:25-28.
35. Swenson, J., J. H. Jorgensen, M. J. Ferraro, and F. C. Tenover. 1997. Activity of newer fluoroquinolones against recent clinical isolates of ofloxacin-resistant Streptococcus pneumoniae, abstr. E-62, p. 124. In Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
36. Tankovic, J., B. Perichon, J. Duval, and P. Courvalin. 1997. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro. Antimicrob. Agents Chemother. 40:2505-2510.
37. Thomson, K. S., S. A. Chartrand, C. C. Sanders, and S. L. Block. 1997. Trovafloxacin, a new fluoroquinolone with potent activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:478-480.
38. Wakabayashi, E., and S. Mitsuhashi. 1994. In vitro antibacterial activity of AM-1155, a novel 6-fluoro-8-methoxy quinolone. Antimicrob. Agents Chemother. 38:594-601.
39. Wise, R. 1991. Comparative penetration of selected fluoroquinolones into respiratory tract fluids and tissues. Am. J. Med. 91:675-705.
40. Wise, R., and D. Honeybourne. 1996. A review of the penetration of sparfloxacin into the lower respiratory tract and sinuses. J. Antimicrob. Chemother. 37(Suppl. A):57-63.
41. Woodcock, J. M., J. M. Andrews, F. J. Boswell, N. P. Brenwald, and R. Wise. 1997. In vitro activity of moxifloxacin, a new fluoroquinolone. Antimicrob. Agents Chemother. 41:101-106.
42. Yonezawa, M., M. Takahata, N. Matsubara, Y. Watanabe, and H Narita. 1995. DNA gyrase gyrA mutations in quinolone-resistant clinical isolates of Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 39:1970-1972.
43. Zeller, V., C. Janoir, M.-D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978.